Business
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi
About this update from Shin Nippon Biomedical Laboratories, Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device.","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Atzumi is the first and only product utilizing the SMART (Simple MucoAdhesive Release Technology) platform which combines a proprietary advanced powder and device technology to simplify delivery of DHE.","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"In clinical studies, Atzumi administration provided rapid and sustained DHE concentrations with low variability.","length":117,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":531,"olType":false},{"type":"text","content":"DURHAM, N.C., April 30, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.","length":582,"tagName":"p"},{"type":"image","alt":"Satsuma Pharmaceuticals (PRNewsfoto/Satsuma Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Satsuma Pharmaceuticals (PRNewsfoto/Satsuma Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":134,"url":"https://media.zenfs.com/en/prnewswire.com/ed276b4d8c5d5ff23262200455ca2c21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2PhjRVul25B4XKRuPr5bhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ed276b4d8c5d5ff23262200455ca2c21","width":400,"height":134}},"href":"https://mma.prnewswire.com/media/2431621/Satsuma_Pharmaceuticals_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Migraine is a neurological disorder that is thought to be the result of temporary changes in the chemicals, nerves and blood vessels in the brain, with symptoms that are often incapaci...